Articles tagged with: PD 0332991

News»

[ by | Jan 5, 2011 12:52 pm | Comments Off ]
Experimental Drug PD 0332991 Shows Encouraging Phase 1 Trial Results In Relapsed/Refractory Multiple Myeloma Patients (ASH 2010)

The results of a Phase 1 trial suggest that the experimental drug PD 0332991 may be a safe and effective treatment for pre-treated multiple myeloma patients.

Dr. Ruben Niesvizky of the Weill Cornell Medical College, who presented the results at the American Society of Hematology (ASH) annual meeting in Orlando last month, pointed out that data about efficacy is limited at this point because it was a Phase 1 trial. However, he added “We are encouraged [by the results] because we have seen two very good partial responses.”

PD 0332991, which is …

Read the full story »

News»

[ by and | Dec 8, 2010 10:46 pm | Comments Off ]
ASH 2010 Multiple Myeloma Update – Day Three Afternoon And Evening

This Monday was the third full day of the American Society of Hematology 2010 annual meeting, and it was packed with multiple myeloma-related presentations.  The Beacon published an update earlier today covering presentations made Monday morning.  This article covers material from Monday afternoon and evening.

The first presentation of the afternoon was by Dr. Ruben Niesvizky of the Weill Cornell Medical College in New York.  He reported on the results of a Phase 3 trial using Velcade (bor­tez­o­mib)-based initial treat­ment (induction) regi­mens com­bined with weekly Velcade main­te­nance ther­apy (abstract).

Patients in this trial were newly …

Read the full story »